Galectin Therapeutics

GALTNasdaq United States Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$347.931 M

$3.45 +7.14%

Close of 7 Aug 2026

Revenue

—

Not reported

Earnings

-$30.8M

Loss-making

Shares outstanding

65,827,448

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations — ranked by market cap

All 501 →

#228Lyell ImmunopharmaLYEL$360.5M
#229Foghorn TherapeuticsFHTX$356.4M
#230Galectin TherapeuticsGALT$347.9M
#231Perspective TherapeuticsCATX$342.1M
#232Turn TherapeuticsTTRX$310.1M

Where these numbers come from

Share counts and financials for Galectin Therapeutics are taken from its own SEC filings via EDGAR — public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 9 Aug 2026. Read the methodology.